Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]
Status PubMed-not-MEDLINE Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu tisková chyba
PubMed
34756500
DOI
10.1016/j.ejca.2021.10.002
PII: S0959-8049(21)01124-2
Knihovny.cz E-zdroje
- Publikační typ
- tisková chyba MeSH
At Time of Research Pfizer Inc Boulder CO USA
Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan
Department of Medical Oncology Isala Oncological Center Zwolle Netherlands
Eberhard Karls University Tuebingen Germany
Hannover Medical School Hannover Germany
Hospital Clinic of Barcelona Barcelona Spain
Institute Gustave Roussy Villejuif France
Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli Italy
Massachusetts General Hospital Boston MA USA
National and Kapodistrian University of Athens Laikon Hospital Athens Greece
National Institute of Oncology Budapest Hungary
Oncology Institute of Veneto IRCCS Padua Italy
Pierre Fabre Medicament Boulogne Billancourt France
Unit of Medical Oncology University of Perugia Perugia Italy
University Hospital Centre Bordeaux Hôpital Saint Andre´ Bordeaux France
University Hospital Essen Essen Germany; German Cancer Consortium Heidelberg Germany
University Hospital Prague and Charles University 1st Medical Faculty Prague Czech Republic
University Hospital Zürich Skin Cancer Center Zürich Switzerland
Citace poskytuje Crossref.org
